DRL-Header DRL-Header


Find Drugs for Cardiology/Vascular Diseases in Phase II Clinical Development in AUSTRALIA


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): CYP-002

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020


            Cynata Therapeutics (CYP) has received approval from the U.K. Medicines and Healthcare products Regulatory Agency to begin the phase 2 trial of CYP-002.